Haemophilus influenzae type b polyribosyl-ribitol-phosphate capsule conjugated to protein carrier (Hib PRP-protein conjugate)

The Haemophilus influenzae type b polyribosyl-ribitol-phosphate (PRP) capsule conjugated to a protein carrier is not a biological receptor, enzyme, or endogenous molecular target. Instead, it is a vaccine antigen composed of the Hib capsular polysaccharide—a linear copolymer of polyribosyl-ribitol-phosphate (PRP)—chemically linked to a carrier protein such as tetanus toxoid or meningococcal outer membrane protein[1][3][4][7][8]. Conjugation enables the polysaccharide to elicit a T cell-dependent immune response, making it immunogenic in infants who would otherwise not respond well to non-conjugated polysaccharide antigens. This conjugate forms the basis of all modern Hib vaccines and is responsible for the dramatic decline in invasive Hib diseases in immunized populations[3][4][7]. As a component of a prophylactic vaccine, its function is to induce protective anti-PRP antibodies, rather than to serve as a therapeutic target in the classical sense (e.g., as a receptor or pathogenic driver). Thus, while essential for vaccine design and population health, it is not a therapeutic target as typically defined in pharmacology.

Other names

Hib capsule conjugatePRP-protein conjugateHaemophilus influenzae type b conjugate vaccineHib PRP-T (when conjugated to tetanus toxoid)Hib PRP-OMP (when conjugated to meningococcal outer membrane protein)

Induces production of anti-PRP antibodies via T cell-dependent immune response following conjugation of capsular polysaccharide to a protein carrier